Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Gynecologic 1Gastrointestinal 1

Conditions

Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Rhabdomyosarcoma 1Ovarian Neoplasms 1Neurofibrosarcoma 1Malignant mesenchymal tumor 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Fibrosarcoma 1

Interventions

Doxorubicin 4Ifosfamide 3Radiotherapy 2Ipilimumab 2Filgrastim 2saracatinib 1perifosine 1pembrolizumab 1fludarabine 1brostallicin 1belinostat 1aldesleukin 1Trabectedin 1Temozolomide 1Sunitinib 1Ritonavir 1Nivolumab 1Mass Spectrometry 1Injections 1Indinavir 1Imatinib Mesylate 1Fluorouracil 1Cyclophosphamide 1Chromatography, High Pressure Liquid 1Chemotherapy, Adjuvant 1CTLA-4 Antigen 1BI 2536 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Histiocytoma, Malignant Fibrous × brostallicin × Gynecologic × Clear all
NCT00410462 2014-08-08

Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Unknown
118 enrolled
GynecologicSarcoma

Malignant mesenchymal tumor, Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Ovarian Neoplasms, Rhabdomyosarcoma, Sarcoma, Sarcoma, Synovial, Sarcoma, Alveolar Soft Part, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡